NASDAQ$GPCR
Structure Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Structure Therapeutics Inc reported increased R&D spending and a wider net loss for Q2 2025.
The company continued advancing its clinical pipeline including Phase 2b studies for aleniglipron. Operating expenses rose substantially year-over-year driven by R&D. The company maintained a strong cash position to fund operations.
- R&D expenses increased to $54.7 million from $22.1 million in Q2 2024.
- Net loss widened to $61.7 million compared to $26.0 million in the prior year period.
- Cash and cash equivalents were $147.0 million as of June 30, 2025.
- Topline data from Phase 2b ACCESS and ACCESS II studies expected in Q4 2025.
Headline financials
Revenue & EPS history
Structure Therapeutics · Revenue · Quarterly
$0
Forward guidance
Company expects to report topline data from Phase 2b studies in Q4 2025 and initiate additional aleniglipron studies.
Tailwinds
- Strong cash position to fund operations through at least 2027
- Positive Phase 2a obesity data reported
Headwinds
- Continued net losses and increased expenses
- No product revenue expected in near term
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports
+1.2%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+9.8%
Avg return
30 days after
44%
7 / 16 earnings
Positive
+14.8%
Q4 2024
Best reaction
-11.6%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | +0.6% | — | — | |
| Q4 2026 | -2.6% | -2.5% | -29.1% | |
| Q3 2025 | -2.0% | +7.3% | +3.3% | |
| Q1 2025 | -4.6% | -11.2% | -21.2% | |
| Q4 2024 | +14.8% | +13.1% | -0.6% | |
| Q3 2024 | +1.9% | -14.1% | -15.5% | |
| Q2 2024 | -0.8% | +0.9% | +8.6% | |
| Q1 2024 | -8.7% | -9.0% | +35.3% | |
| Q4 2023 | -2.5% | -5.9% | +15.1% | |
| Q3 2022 | +11.5% | +7.1% | +23.4% | |
| Q3 2023 | -11.6% | -1.6% | +7.2% | |
| Q2 2022 | -1.9% | -2.9% | -0.1% | |
| Q2 2023 | -1.9% | -2.9% | -0.1% | |
| Q1 2023 | +8.9% | +1.9% | +40.2% | |
| Q1 2022 | +8.9% | +1.9% | +40.2% | |
| Q4 2022 | +8.9% | +1.9% | +40.2% | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro